

Solexa, Inc.
Form 425
January 10, 2007

Table of Contents

Filed by Illumina, Inc.
pursuant to Rule 425
under the Securities Act of 1933 and
deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934

Subject Company: Solexa, Inc.
Commission File No. 333-139111

TABLE OF CONTENTS

Highlights of Breakout Year in 2006
Non-GAAP Q3 Financial Performance
ASP for Infinium Product Family
Rapid Growth in Installed Base
2006 New Products in Infinium™ Family
Recent Deal Summary
Comprehensive Suite of Gene Expression Products
Diagnostic Partnerships
Creating A Powerful Life Science Franchise
Solexa's Technology
Solexa Technical Approach
Key Technology Advantages
Integration of Sequencing and Genotyping
Recent Developments and Progress
Financial Highlights of Transaction
Launch of DNA Methylation Application
DNA Methylation
Methylation Product Offering
Methylation Profiles of Cancer Cell Lines
Biomarkers for Cancer Cell Lines
Technology / Platform Synergy
Digital Code Generation
Beads Align in Groove Plate
Code Detection
Three Initial Kits for Research Market
Distribution, Chemistry and Content Synergy
The Near-Term Future of Infinium Product Line
What Factors are Important in the Market?
Illumina's Human 1M BeadChip
Human 1M BeadChip Content
Upgradeable and Compatible Products
Summary

Table of Contents



Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents